ATE416756T1 - Methoden zur verwendung von lamellaren körpern für therapeutische zwecke - Google Patents

Methoden zur verwendung von lamellaren körpern für therapeutische zwecke

Info

Publication number
ATE416756T1
ATE416756T1 AT03722717T AT03722717T ATE416756T1 AT E416756 T1 ATE416756 T1 AT E416756T1 AT 03722717 T AT03722717 T AT 03722717T AT 03722717 T AT03722717 T AT 03722717T AT E416756 T1 ATE416756 T1 AT E416756T1
Authority
AT
Austria
Prior art keywords
methods
therapeutic purposes
lamellar body
lamellar
therapeutic
Prior art date
Application number
AT03722717T
Other languages
English (en)
Inventor
James Dobbie
Original Assignee
Lamellar Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamellar Biomedical Ltd filed Critical Lamellar Biomedical Ltd
Application granted granted Critical
Publication of ATE416756T1 publication Critical patent/ATE416756T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03722717T 2002-04-03 2003-04-02 Methoden zur verwendung von lamellaren körpern für therapeutische zwecke ATE416756T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207653.7A GB0207653D0 (en) 2002-04-03 2002-04-03 Methods of using lamellar bodies for therapeutic purposes

Publications (1)

Publication Number Publication Date
ATE416756T1 true ATE416756T1 (de) 2008-12-15

Family

ID=9934144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722717T ATE416756T1 (de) 2002-04-03 2003-04-02 Methoden zur verwendung von lamellaren körpern für therapeutische zwecke

Country Status (11)

Country Link
US (1) US7906139B2 (de)
EP (2) EP2177212B1 (de)
JP (1) JP4657608B2 (de)
AT (1) ATE416756T1 (de)
AU (1) AU2003229881A1 (de)
DE (1) DE60325194D1 (de)
DK (1) DK1492501T3 (de)
ES (2) ES2319276T3 (de)
GB (1) GB0207653D0 (de)
PT (1) PT1492501E (de)
WO (1) WO2003082245A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2540328C (en) * 2003-09-25 2012-11-20 Lamellar Therapeutics Limited Compositions and methods of using lamellar bodies for therapeutic purposes
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
FR2921253B1 (fr) * 2007-09-26 2012-11-16 Lvmh Rech Composition cosmetique sous la forme d'une emulsion comprenant une phase aqueuse continue et une phase grasse dispersee et son procede de preparation
DE102008005172A1 (de) * 2008-01-19 2009-07-23 Mike Ehrlich Pharmazeutische Zusammensetzung zur Verhinderung von post-operativen Adhäsionen
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
WO2015200355A1 (en) * 2014-06-24 2015-12-30 Saint Louis University Methods for reducing fibrosis induced by peritoneal dialysis
WO2019068843A1 (en) * 2017-10-06 2019-04-11 Sime Diagnostics Ltd. PURIFICATION OF LAMELLAR BODY FOR THE DIAGNOSIS AND TREATMENT OF DISEASE OR DISORDER
US20210145741A1 (en) * 2018-04-17 2021-05-20 Lamellar Biomedical Limited Antifibrotic composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
JPH01295933A (ja) 1989-03-25 1989-11-29 Toto Ltd 衛生洗浄装置
JPH02295933A (ja) * 1989-05-10 1990-12-06 Wakamoto Pharmaceut Co Ltd 封入純度の高いプラスミノーゲン活性化因子封入リポソームの製造法
WO1991012026A1 (en) * 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
EP0721328A4 (de) * 1993-09-27 1997-09-17 Smithkline Beecham Corp Camptothecin-formulierungen
US5462752A (en) 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
CN1119145C (zh) * 1995-10-11 2003-08-27 埃斯佩里安Luv发展公司 脂质体组合物及其使用方法
AU7685798A (en) * 1997-05-29 1998-12-30 Applied Biotechnologies Inc. Compositions and methods for preventing adhesion
SE9702698D0 (sv) 1997-07-14 1997-07-14 Stig Bengmark Compositions for lubricating and separating tissues and biological membranes
GB9807298D0 (en) * 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2000069412A1 (en) * 1999-05-14 2000-11-23 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments

Also Published As

Publication number Publication date
US7906139B2 (en) 2011-03-15
EP2177212B1 (de) 2013-03-06
WO2003082245A1 (en) 2003-10-09
DE60325194D1 (de) 2009-01-22
PT1492501E (pt) 2009-03-26
EP1492501B1 (de) 2008-12-10
EP1492501A1 (de) 2005-01-05
ES2409757T3 (es) 2013-06-27
US20040126420A1 (en) 2004-07-01
EP2177212A1 (de) 2010-04-21
ES2319276T3 (es) 2009-05-06
AU2003229881A1 (en) 2003-10-13
GB0207653D0 (en) 2002-05-15
JP4657608B2 (ja) 2011-03-23
JP2005526101A (ja) 2005-09-02
DK1492501T3 (da) 2009-04-06

Similar Documents

Publication Publication Date Title
NO2022001I1 (no) Pazopanib
BR0315689A (pt) Alvo para terapia de dano cognitivo
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE602004027600D1 (de) Genexpressionsmarker für die prognose von brustkrebs
DE602004023229D1 (de) Mais metallothionen promoter 2 und methoden zur verwendung
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
DE602004027637D1 (de) Verwendung von cupredoxin-proteine für krebstherapie
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE452655T1 (de) Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
ATE446314T1 (de) Methode zur reinigung von fsh
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE366045T1 (de) Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
DE60334839D1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
SE0301650D0 (sv) Novel compounds
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
ATE328000T1 (de) Phospholipidester von clofarabin
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1492501

Country of ref document: EP